Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

Parameter

Placebo (n = 65)

AZL-M 40 mg (n = 132)

AZL-M 80 mg (n = 130)

Total (N = 327)

Age, mean (SD), yearsa

58.8 (10.2)

59.8 (10.8)

58.3 (11.6)

59.0 (11.0)

  < 65 years, n (%)

44 (67.7)

82 (62.1)

89 (68.5)

215 (65.7)

  ≥ 65 years, n (%)

21 (32.3)

50 (37.9)

41 (31.5)

112 (34.3)

Sex, n (%)

 Male

51 (78.5)

95 (72.0)

93 (71.5)

239 (73.1)

 Female

14 (21.5)

37 (28.0)

37 (28.5)

88 (26.9)

Height, mean (SD), cm

166.1 (8.4)

164.8 (9.1)

165.6 (8.0)

165.4 (8.5)

Weight, mean (SD), kgb

70.9 (9.9)

71.0 (12.6)

70.3 (13.1)

70.7 (12.3)

BMI, mean (SD), kg/m2c

25.64 (2.7)

26.02 (3.3)

25.50 (3.5)

25.74 (3.2)

eGFR, mean (SD), mL/min/1.73 m2

85.7 (14.8)

87.4 (18.4)

88.7 (18.4)

87.6 (17.7)

Diabetes status, n (%)

 Yes

4 (6.2)

21 (15.9)

13 (10.0)

38 (11.6)

 No

61 (93.8)

111 (84.1)

117 (90.0)

289 (88.4)

Concomitant medication, n (%)d

 Medication continued into double-blind treatment period

26 (40.0)

50 (37.9)

57 (43.8)

133 (40.7)

 Initiated use during double-blind treatment period

43 (66.2)

87 (65.9)

89 (68.5)

219 (67.0)

Smoking classification, n (%)

 Never smoked

29 (44.6)

71 (53.8)

65 (50.0)

165 (50.5)

 Ex-smoker

24 (36.9)

39 (29.5)

39 (30.0)

102 (31.2)

 Current smoker

12 (18.5)

22 (16.7)

26 (20.0)

60 (18.3)

scSBP, mean (SD), mmHge

158.8 (7.4)

158.9 (8.0)

160.1 (7.4)

159.4 (7.6)

scDBP, mean (SD), mmHgf

94.3 (11.0)

93.1 (9.6)

93.2 (9.5)

93.4 (9.8)

  1. AZL-M azilsartan medoxomil, BMI body mass index, eGFR estimated glomerular filtration rate, scSBP sitting clinic systolic blood pressure, scDBP sitting clinic diastolic blood pressure, SD standard deviation
  2. aAge at date of signing informed consent form. bWeight was measured before the first dose of double-blind study drug. cBMI was calculated from the weight taken before the first dose of study drug and height taken at screening. dNo clinically meaningful differences were observed between treatment groups in the percentages of patients taking concomitant medications. eNo statistical difference in scSBP was observed between treatment groups (p = 0.56). fNo statistical difference in scDBP was observed between treatment groups (p = 0.87)